[go: up one dir, main page]

MX2018001014A - Sales y profarmacos de 1-metil-d-triptofano. - Google Patents

Sales y profarmacos de 1-metil-d-triptofano.

Info

Publication number
MX2018001014A
MX2018001014A MX2018001014A MX2018001014A MX2018001014A MX 2018001014 A MX2018001014 A MX 2018001014A MX 2018001014 A MX2018001014 A MX 2018001014A MX 2018001014 A MX2018001014 A MX 2018001014A MX 2018001014 A MX2018001014 A MX 2018001014A
Authority
MX
Mexico
Prior art keywords
salts
indoximod
prodrugs
tryptophan
methyl
Prior art date
Application number
MX2018001014A
Other languages
English (en)
Inventor
Mautino Mario
Waldo Jesse
Jaipuri Firoz
Kumar Sanjeev
Zhuang Hong
POTTURI Hima
Original Assignee
Newlink Genetics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Newlink Genetics Corp filed Critical Newlink Genetics Corp
Publication of MX2018001014A publication Critical patent/MX2018001014A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an alkyl or cycloalkyl radical attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/285—Arsenic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/20—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic unsaturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
    • C07F9/6574—Esters of oxyacids of phosphorus
    • C07F9/65742—Esters of oxyacids of phosphorus non-condensed with carbocyclic rings or heterocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06043—Leu-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/0606—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06104—Dipeptides with the first amino acid being acidic

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

En la presente se proporcionan compuestos de profármacos y sales de indoximod y composiciones farmacéuticas que comprenden las sales y los profármacos de indoximod, que producen mejor concentración y exposición en plasma a indoximod en comparación con la administración directa de indoximod, en pacientes que necesitan tratamiento de inmunosupresión mediada por la vía indolamina-2,3-dioxigenasa, tales como pacientes con cáncer o enfermedades infecciosas crónicas.
MX2018001014A 2015-07-24 2016-06-02 Sales y profarmacos de 1-metil-d-triptofano. MX2018001014A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562196671P 2015-07-24 2015-07-24
US201662305748P 2016-03-09 2016-03-09
PCT/US2016/035391 WO2017019175A1 (en) 2015-07-24 2016-06-02 Salts and prodrugs of 1-methyl-d-tryptophan

Publications (1)

Publication Number Publication Date
MX2018001014A true MX2018001014A (es) 2018-05-23

Family

ID=57836622

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018001014A MX2018001014A (es) 2015-07-24 2016-06-02 Sales y profarmacos de 1-metil-d-triptofano.

Country Status (24)

Country Link
US (4) US9732035B2 (es)
EP (4) EP4659747A2 (es)
JP (4) JP6842429B2 (es)
KR (2) KR20180030825A (es)
CN (2) CN111004167B (es)
AU (1) AU2016298471C1 (es)
BR (1) BR112018000225A2 (es)
CA (3) CA2992016C (es)
CL (1) CL2018000082A1 (es)
CO (1) CO2017013724A2 (es)
CR (1) CR20180023A (es)
DO (1) DOP2018000011A (es)
EA (1) EA201792256A1 (es)
EC (1) ECSP18002561A (es)
ES (2) ES2923184T3 (es)
HK (2) HK1247844A1 (es)
IL (2) IL255625B (es)
MA (1) MA43294A1 (es)
MX (1) MX2018001014A (es)
NZ (1) NZ736978A (es)
PE (1) PE20180928A1 (es)
PH (1) PH12017502046A1 (es)
WO (1) WO2017019175A1 (es)
ZA (1) ZA201800208B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2992016C (en) 2015-07-24 2019-10-22 Newlink Genetics Corporation Salts and prodrugs of 1-methyl-d-tryptophan
CN109400517A (zh) * 2017-08-17 2019-03-01 上海时莱生物技术有限公司 1-甲基-色氨酸类化合物及其制备方法和用途
EP3681498B1 (en) * 2017-09-14 2022-10-05 Lankenau Institute for Medical Research Methods and compositions for the treatment of cancer
CN109646683A (zh) * 2019-02-27 2019-04-19 武汉理工大学 一种1-mt-羧甲基壳聚糖药物的制备方法
AU2020384481B2 (en) 2019-11-12 2025-12-11 Nammi Therapeutics, Inc. Formulated and/or co-formulated liposome compositions containing IDO antagonist prodrugs useful in the treatment of cancer and methods thereof
CA3194742A1 (en) 2020-09-10 2022-03-17 Nammi Therapeutics, Inc. Formulated and/or co-formulated liposome compositions containing pd-1 antagonist prodrugs useful in the treatment of cancer and methods thereof
KR20250029575A (ko) 2023-08-23 2025-03-05 한국과학기술원 카메라 시스템의 동적 환경에 강인한 자기 위치 추정 장치 및 그 방법

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US14139A (en) 1856-01-22 Method oe ventilating railroad-cabs
GB1330573A (en) 1970-09-12 1973-09-19 Ajinomoto Kk Optical resolution of dl-tryptophan derivatives
US4072691A (en) 1974-01-12 1978-02-07 Tanabe Seiyaku Co., Ltd. Process for the resolution of DL-6-chlorotryptophan
US5185157A (en) 1990-05-02 1993-02-09 Caston John C Treatment of refractory Eosinophilia-Myalgia Syndrome with L-tryptophan composition
WO1996011927A1 (en) 1994-10-12 1996-04-25 Abbott Laboratories Endothelin antagonists
US6451840B1 (en) 1997-12-05 2002-09-17 Medical College Of Georgia Research Institute, Inc. Regulation of T cell-mediated immunity by tryptophan
MXPA02008931A (es) * 2000-03-16 2003-02-10 Hoffmann La Roche Derivados de acido carboxilico como antagonistas ip.
ATE397606T1 (de) * 2001-06-05 2008-06-15 Lilly Icos Llc Pyrazino(1',2':1,6)-pyrido(3,4-b) indole-1,4- dionderivate
WO2004093871A1 (en) 2003-03-27 2004-11-04 Lankenau Institute For Medical Research Novel methods for the treatment of cancer
US7598287B2 (en) 2003-04-01 2009-10-06 Medical College Of Georgia Research Institute, Inc. Use of inhibitors of indoleamine-2,3-dioxygenase in combination with other therapeutic modalities
JO2625B1 (en) * 2003-06-24 2011-11-01 ميرك شارب اند دوم كوربوريشن Phosphoric acid salts of dipeptidyl betidase inhibitor 4
EP1707560A4 (en) 2003-12-25 2007-10-17 Kureha Corp HYDROXAMIC ACID DERIVATIVE AND THE DERIVATIVE INHIBITOR OF THE GENERATION OF AGE
CN101212967A (zh) 2005-05-10 2008-07-02 因塞特公司 吲哚胺2,3-双加氧酶调节剂及其用法
WO2007081878A2 (en) * 2006-01-07 2007-07-19 Medical College Of Georgia Research Institute, Inc. Indoleamine 2,3-dioxygenase pathways in the generation of regulatory t cells
US7705022B2 (en) 2005-10-27 2010-04-27 Lankenau Institute For Medical Research IDO inhibitors and methods of use thereof
ES2540561T3 (es) 2005-12-20 2015-07-10 Incyte Corporation N-hidroxiamidinoheterociclos como moduladores de indolamina 2,3-dioxigenasa
CA2569204A1 (en) 2006-11-28 2008-05-28 Apotex Technologies Inc. Crystalline d-isoglutamyl-d-tryptophan and the mono ammonium salt of d-isoglutamyl-d-tryptophan
US20100055111A1 (en) * 2007-02-14 2010-03-04 Med. College Of Georgia Research Institute, Inc. Indoleamine 2,3-dioxygenase, pd-1/pd-l pathways, and ctla4 pathways in the activation of regulatory t cells
EP2137168B1 (en) 2007-03-16 2016-09-14 Lankenau Institute for Medical Research Novel ido inhibitors and methods of use thereof
EP2227233B1 (en) 2007-11-30 2013-02-13 Newlink Genetics Ido inhibitors
ATE514671T1 (de) * 2008-02-01 2011-07-15 Firmenich & Cie Substituierte cyclohexenone
CA2722159C (en) 2008-04-24 2016-04-05 Newlink Genetics Corporation Substituted phenylimidazole compounds and their use as ido inhibitors
CN104042611B (zh) 2008-07-08 2019-05-14 因塞特控股公司 作为吲哚胺2，3-双加氧酶的抑制剂的1，2，5-噁二唑
KR20180028070A (ko) 2009-05-13 2018-03-15 길리애드 파마셋 엘엘씨 항바이러스 화합물
ES2601226T3 (es) 2009-10-28 2017-02-14 Newlink Genetics Corporation Derivados de imidazol como inhibidores de IDO
WO2011100295A2 (en) * 2010-02-09 2011-08-18 Medical College Of Georgia Research Institute, Inc. Alpha-methyl-tryptophan as an inhibitor of indoleamine dioxygenase
NO2694640T3 (es) 2011-04-15 2018-03-17
JO3353B1 (ar) 2012-04-20 2019-03-13 Ono Pharmaceutical Co شكل صلب معزول من أحادي هيدروكلوريد أناموريلين بنسبة مولارية منخفضة من الكلوريد: أناموريلين ومحتوى منخفض من مذيب عضوي متبقي
EP2922847A1 (en) 2012-11-20 2015-09-30 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of indoleamine 2,3-dioxygenase
SG10201707545XA (en) 2013-03-14 2017-10-30 Newlink Genetics Corp Tricyclic compounds as inhibitors of immunosuppression mediated by tryptophan metabolization
SG11201507395PA (en) 2013-03-14 2015-10-29 Curadev Pharma Private Ltd Inhibitors of the kynurenine pathway
WO2014141110A2 (en) 2013-03-14 2014-09-18 Curadev Pharma Pvt. Ltd. Aminonitriles as kynurenine pathway inhibitors
AU2014235750B2 (en) 2013-03-15 2018-05-17 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase (IDO)
CA2907178A1 (en) 2013-03-15 2014-09-25 Bristol-Myers Squibb Company Ido inhibitors
MX2015017486A (es) 2013-07-01 2016-03-21 Squibb Bristol Myers Co Inhibidores de indolamina 2,3-dioxigenasa (dio).
CN105517999B (zh) 2013-07-11 2019-06-28 百时美施贵宝公司 Ido抑制剂
CA2992016C (en) 2015-07-24 2019-10-22 Newlink Genetics Corporation Salts and prodrugs of 1-methyl-d-tryptophan
EP3426633A4 (en) 2016-03-09 2020-03-04 Emory University Elimination of hepatitis b virus with antiviral agents
WO2018006035A1 (en) 2016-06-30 2018-01-04 Timpson Electrical & Aerial Services, LLC High voltage training device and system and method thereof

Also Published As

Publication number Publication date
ES2923184T3 (es) 2022-09-26
WO2017019175A1 (en) 2017-02-02
US20170022157A1 (en) 2017-01-26
US11485705B2 (en) 2022-11-01
EP3954369A1 (en) 2022-02-16
CO2017013724A2 (es) 2018-03-28
EP3954369C0 (en) 2025-08-20
US9732035B2 (en) 2017-08-15
EP3613420A1 (en) 2020-02-26
JP2019011381A (ja) 2019-01-24
CA3051388A1 (en) 2017-02-02
PH12017502046A1 (en) 2018-04-23
MA43294A1 (fr) 2020-04-30
BR112018000225A2 (pt) 2018-09-04
JP7286299B2 (ja) 2023-06-05
EP3324958B1 (en) 2021-07-28
US10207990B2 (en) 2019-02-19
HK1247844A1 (zh) 2018-10-05
KR20180086300A (ko) 2018-07-30
NZ736978A (en) 2019-06-28
EP3613420B1 (en) 2022-05-25
AU2016298471A1 (en) 2017-11-23
IL255625B (en) 2019-08-29
JP2023060349A (ja) 2023-04-27
JP2018522830A (ja) 2018-08-16
CR20180023A (es) 2018-03-20
EA201792256A1 (ru) 2018-07-31
EP4659747A2 (en) 2025-12-10
US20190248739A1 (en) 2019-08-15
CA2992016A1 (en) 2017-02-02
ES2894334T3 (es) 2022-02-14
EP3954369B1 (en) 2025-08-20
KR20180030825A (ko) 2018-03-26
JP6842429B2 (ja) 2021-03-17
US20200283385A1 (en) 2020-09-10
AU2016298471B2 (en) 2019-08-22
CA2992016C (en) 2019-10-22
EP3324958A1 (en) 2018-05-30
IL255625A (en) 2018-01-31
JP2021121633A (ja) 2021-08-26
CL2018000082A1 (es) 2018-06-15
CN111004167B (zh) 2024-03-22
HK1247837A1 (zh) 2018-10-05
CA3132620C (en) 2024-03-05
CN107847486A (zh) 2018-03-27
CN111004167A (zh) 2020-04-14
ZA201800208B (en) 2018-12-19
US20180134658A1 (en) 2018-05-17
DOP2018000011A (es) 2018-04-30
CA3132620A1 (en) 2017-02-02
ECSP18002561A (es) 2018-03-31
IL268048A (en) 2019-09-26
PE20180928A1 (es) 2018-06-08
EP3324958A4 (en) 2018-10-24
CA3051388C (en) 2021-11-09
AU2016298471C1 (en) 2020-03-05

Similar Documents

Publication Publication Date Title
DOP2018000011A (es) Sales y profármacos de 1-metil-d-triptófano
CL2020000501A1 (es) Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp1) y usos de los mismos.
CY1122946T1 (el) Μεθοδοι για θεραπεια filoviridαε ιου μολυνσεων
ECSP20033467A (es) Compuestos macrocíclicos para tratar enfermedades
DOP2015000241A (es) Compuestos de biaril-amida como inhibidores de cinasa
MX391858B (es) Compuestos terapeuticamente activos y sus metodos de uso
CO2018009382A2 (es) Eliminación del virus de la hepatitis b con agentes antivirales
SV2017005489A (es) Terapias de combinación para el tratamiento de cánceres
MX2016013689A (es) Compuestos 4-amino-imidazoquinolina.
CR20150316A (es) Compuestos y sus métodos de empleo
GT201500312A (es) Derivados de sulfamoilpirrolamida y su uso como medicamentos para el tratamiento de la hepatitis b
MX2016011810A (es) Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso.
DOP2014000188A (es) Derivados macrocíclicos para el tratamiento de enfermedades
CU20160020A7 (es) Derivados de imidazoquinolinas sustituidas inhibidores de mek para el tratamiento del cáncer
ECSP17013903A (es) Protein kinase c inhibitors and methods of their use
BR112017009552A8 (pt) Métodos para alvejar o controle transcricional em regiões de super-realçador
DOP2017000049A (es) Compuestos tricíclicos que contienen nitrógeno para el tratamiento de la infección por neisseria gonorrhoeae
MX2022014792A (es) Cocristales, composiciones farmaceuticas de los mismos y metodos de tratamiento que los implican.
MX2023012640A (es) Uso de profarmacos de riluzol para tratar ataxias.
MX2017003788A (es) Derivados de nucleósidos sustituidos con 4´-vinilo como inhibidores de la replicación del arn del virus respiratorio sincitial.
CR20160529A (es) Composiciones farmacéuticas para tratar enfermedades infecciosas
PE20160596A1 (es) Formulacion de atazanavir y cobicistat para el tratamiento del virus de inmunodeficiencia humana
BR112017016333A2 (pt) compostos anticâncer
GT201400071A (es) Combinación terapéutica para el tratamiento de cáncer
CU20140107A7 (es) Derivados macrocíclicos para el tratamiento de enfermedades